Randomized controlled study on the treatment of mild to moderate depression with Xiaoyao Mixture

Jinan University0 个研究点目标入组 108 人开始时间: 2024年4月11日最近更新: 2024年4月22日

试验速览

暂无简介。

•1. Meet the diagnostic criteria for depression in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) with a HAMD-17 score between 7 and 24 points.
•2. Meet the diagnosis criteria for liver depression and spleen deficiency syndrome;
•3. Patients aged 16-65 years, regardless of gender;
•4. Patients are voluntary, have informed consent, and have good compliance.

•1. Patients with bipolar depression, refractory depression, or suicidal tendency (item 3 score of HAMD scale > 2 points);
•2. Patients with other mental disorders such as organic mental disorders, schizophrenia, depression disorders caused by psychoactive substances and non-addictive substances;
•3. Patients with severe organ lesions such as heart, liver and kidney, hematological diseases or tumors;
•4. Patients who have received systematic treatment within 2 weeks before enrollment;
•5. Pregnant or lactating women, or those who require fertility during the trial;
•6. Patients who are participating in other clinical trials or have participated in other drug clinical trials within 3 months before screening;
•7. Patients with a known or suspected allergy to the investigational drugs and excipients, or hypersensitivity constitution (defined as allergy to at least 2 drugs);
•8. Patients who used fluoxetine within 4 weeks before enrollment;
•9. Other situations that the researchers consider unsuitable for participating in this trial.

发起方

Jinan University